Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
COMPLETED
NCT05447676
EARLY_PHASE1

Effects of 4-AP on Functional SCI Recovery

Sponsor: Shirley Ryan AbilityLab

View on ClinicalTrials.gov

Summary

The purpose of this study is to test a strategy to potentiate functional recovery of lower limb motor function in individuals with spinal cord injury (SCI). The FDA approved drug, Dalfampridine (4-AP). 4-AP will be used in combination of Spike-timing-dependent plasticity (STDP) stimulation and STDP stimulation with limb training.

Official title: Effects of 4-AP on Functional Recovery After Spinal Cord Injury

Key Details

Gender

All

Age Range

18 Years - 85 Years

Study Type

INTERVENTIONAL

Enrollment

26

Start Date

2022-06-30

Completion Date

2025-06-30

Last Updated

2026-06-03

Healthy Volunteers

No

Interventions

DRUG

Dalfampridine

The study drug (4-AP) will be administered as a 10 mg dose.

OTHER

Placebo drug

The pharmacy will also provide a placebo drug that looks identical to 4-AP to verify participants and therapists do not know who is receiving the drug and who is receiving the placebo.

OTHER

STDP stimulation

Paired stimulation will be given to the spinal cord and to peripheral nerves so that the signals are received at the spinal cord at a specific interval.

BEHAVIORAL

Exercise training

Lower-limb exercises will involve over-ground walking, treadmill, walking and stair climbing training.

Locations (1)

Shirley Ryan Abilitylab

Chicago, Illinois, United States